Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.
The acquisition provides Myriad with the EndoPredict test, which is currently offered in Europe and is expected to launch in the US next year.
The analysis showed that one out of 227 node-negative breast cancer patients with the lowest EPclin scores by Sividon's EndoPredict test experienced recurrence over 10 years.
At the San Antonio Breast Cancer Symposium, a Sividon collaborator is scheduled to present a new study including a comparison between EndoPredict and Oncotype DX.
Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.
Bill Gates tells the Telegraph that bioterrorism is a serious risk.
The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.
CBS News reports that the White House Science Fair is to continue under President Donald Trump.